Microvascular System Articles & Analysis
2 news found
Gesynta Pharma AB ("Gesynta"), a clinical stage company developing novel anti-inflammatory agents, today announced that the results from the successfully completed First-in-Human clinical study with its lead candidate GS-248 for the treatment of microvascular disease have been presented at the EULAR 2020 E-Congress. Following these results, Gesynta now intends to commence a ...
The results support the further clinical development of GS-248 in microvascular dysfunction and a Phase II clinical study in patients with Systemic Sclerosis is being planned. ...